id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2503881,25bcf25e-e2fc-47a9-afb4-e1074837f16b,Q3,HOLLAND & KNIGHT LLP,18466,VIATRIS INC,2020,third_quarter,PHA,"Drug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, Medicare generics penalty, generic drugs, supply chain.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-05T10:52:24.070000-04:00
2503982,12c11c87-aa4b-4691-95fb-80172ab11942,Q3,WATKINS & EAGER PLLC,401104403,"ZYNERBA PHARMACEUTICALS, INC.",2020,third_quarter,PHA,"Support Zynerba and its partners, and any other of its contractors in its process before the FDA; Troubleshoot inevitable issues and eligibility hurdles to ensure the project is considered for approval; Brief staff of FDA throughout process to ensure they have all information needed; Work with Zynerba to formulate the best strategy to work with FDA in preparation for any scheduled meetings.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-05T13:28:00.437000-04:00
2504097,90e37133-7139-4887-a5a5-debd936fafed,Q3,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2020,third_quarter,PHA,"Drug pricing, 340B for children's hospitals","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,35404,0,0,2020-10-05T16:33:48.187000-04:00
2504191,4d31ac54-0cb2-4c61-9b68-ecf507f5d576,Q3,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2020,third_quarter,PHA,"Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2020-10-06T10:10:34.017000-04:00
2504232,dfe6398e-03fc-4b41-9239-007395f97e88,Q3,"RUBICON ADVISORS, LLC",315091,"ASCENDIS PHARMA, INC.",2020,third_quarter,PHA,"Food and Drug Administration, Orphan Drugs",Food & Drug Administration (FDA),60000,,0,0,2020-10-06T11:10:58.677000-04:00
2504238,9b7e35d9-bc2c-4656-90bf-3ec86f407a91,Q3,"RUBICON ADVISORS, LLC",315091,AVET PHARMACEUTICALS,2020,third_quarter,PHA,"GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES",30000,,0,0,2020-10-06T11:18:02.390000-04:00
2504240,2b1b1dac-444f-4459-a719-959ad13a4aaf,Q3,TODD STRATEGY GROUP,401103321,"ALKERMES, INC.",2020,third_quarter,PHA,"Prescription drug pricing.
C.R.8337: Continuing Appropriations Act, 2021.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-06T11:20:04.713000-04:00
2504243,13f7372f-7f9b-40b4-a44c-c384753fa4ae,Q3,"RUBICON ADVISORS, LLC",315091,CONSCIOUS DISCIPLINE,2020,third_quarter,PHA,Medicare,"HOUSE OF REPRESENTATIVES,SENATE",37500,,0,0,2020-10-06T11:22:06.687000-04:00
2504246,7af872d3-e3eb-48d0-9ccb-fd16bd792b69,Q3,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2020,third_quarter,PHA,Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",45000,,0,0,2020-10-06T11:27:08.170000-04:00
2504265,b88e8417-3272-4682-b354-f33920e273e3,Q3,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2020,third_quarter,PHA,"Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA)","HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2020-10-06T11:50:17.690000-04:00
2504268,7735c51e-3378-479f-8d4b-984a76f8be6f,Q3,TODD STRATEGY GROUP,401103321,BIOTECHNOLOGY INNOVATION ORGANIZATION,2020,third_quarter,PHA,Drug Pricing and Access.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-06T11:53:19.247000-04:00
2504271,5966d649-77d3-491e-bd80-e4c4f1aae79e,Q3,TODD STRATEGY GROUP,401103321,"CAREDX, INC.",2020,third_quarter,PHA,Coverage of immunosuppressive drugs.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",40000,,0,0,2020-10-06T11:54:20.623000-04:00
2504274,ac4d4ce0-f6c3-4c1e-9945-15219a95a955,Q3,"RUBICON ADVISORS, LLC",315091,"LANNETT COMPANY, INC",2020,third_quarter,PHA,"Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",60000,,0,0,2020-10-06T11:55:22.863000-04:00
2504279,4f70bfbb-39af-496e-bfc6-7a523fa6e6e8,Q3,TODD STRATEGY GROUP,401103321,EMD SERONO INC.,2020,third_quarter,PHA,Drug pricing policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-06T11:55:24.323000-04:00
2504289,791110e4-0878-4b73-9fb5-aa580fad1996,3T,"RUBICON ADVISORS, LLC",315091,"PURE BLUE DIAGNOSTICS, A DIVISION OF PURE BLUE MEDICAL",2020,third_quarter,PHA,"Food and Drug Administration, COVID-19 Testing",Food & Drug Administration (FDA),30000,,0,1,2020-10-06T12:04:29.567000-04:00
2504300,18dfa396-679f-4a82-907f-7116557eaa77,Q3,TODD STRATEGY GROUP,401103321,"US WORLDMEDS, LLC",2020,third_quarter,PHA,Opioid Use Disorder Treatment Policy.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-06T12:32:40.033000-04:00
2504482,1afb379e-faa4-4588-92e3-040be3933698,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2020,third_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value. 
Prescription drug importation.
Issues related to regulation of prescription opioid medication.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-06T17:52:10.787000-04:00
2504492,f51ea890-6356-471d-b6fb-84293324f741,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2020,third_quarter,PHA,"Issues related to pharmaceutical market value.
Global supply chain.
Proposed Notice of Benefit and Payment Parameters (NBPP) Rule for 2021.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-06T17:59:15.687000-04:00
2504653,0e14125c-af0d-4f2a-855e-d1980d99bb1b,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2020,third_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2020-10-07T13:29:08.140000-04:00
2505222,93217167-e4a2-4566-9920-a4ddc049d09a,Q3,ACG ADVOCACY,2057,WALGREEN CO.,2020,third_quarter,PHA,"Drug Pricing Policy Issues.
Data privacy and DIR fee reform.
Public Health Crisis.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-08T16:35:48-04:00
2505289,28c01c46-667d-43fc-bd2f-d4269e42a097,Q3,ACG ADVOCACY,2057,"LYNDRA THERAPEUTICS, INC.",2020,third_quarter,PHA,Issues related to advanced pharmaceutical and domestic supply chain.,"Health & Human Services, Dept of (HHS),White House Office",70000,,0,0,2020-10-08T17:20:31.237000-04:00
2505424,66f11261-2a9c-4763-af68-fedada2047f3,Q3,PANNONE LOPES DEVEREAUX & O'GARA LLC,401105501,AMGEN,2020,third_quarter,PHA,Prescription drug pricing.,,9000,,0,0,2020-10-09T10:05:11.183000-04:00
2505570,1f0d9f14-c1ab-4a15-943f-aff8a066af22,3T,TAUZIN STRATEGIC NETWORKS,400786367,CAPTURERX,2020,third_quarter,PHA,Issues related to the 340b program,"HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2020-10-09T12:09:02.527000-04:00
2505677,f5226059-fb54-4c6c-8462-a8e6bc7747a8,Q3,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2020,third_quarter,PHA,In-office Compounding,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-09T12:49:02.517000-04:00
2505996,d5f3a39f-f84e-4db7-a4c7-299acc27ab4d,Q3,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2020,third_quarter,PHA,"Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.

H.R. 8406 - The HEROES ACT (modified) - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID-19 pandemic. 

Senate HEALS Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.

H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications. 

H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.

H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.

H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic. 

HHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.","HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",60000,,0,0,2020-10-11T20:58:02.540000-04:00
2506001,6de10f5a-fea2-45ce-8d41-2b0c5a70d684,Q3,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2020,third_quarter,PHA,"S. 4760 - Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act - Strategies to address problems related to treating currently antibiotic resistant diseases and infections. 

S. 6725 - The National Defense Authorization Act - Issues related to ensuring that there are antibiotics in the pipeline to ensure that our nation's troops are adequately protected from infection-related complications.

H.R. 6800 - THe HEROES Act - Issues related to continuing the fight against SUD and opioid addiction in the time of COVID.  Issues related to ensuring that there were new, effective antibiotics in the pipeline to treat secondary infections due to hospitalizations for COVID.  Issues related to HIT as a tool during the pandemic. 


H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that antibiotics are available during the COVID-19 crisis and beyond and OTC monograph reform is address to enhance patient safety.

H.R. 6201 - Families First Coronavirus Response Act - Implementation-   Issues related to ensuring that the federal government is best supporting the public good with a focus on ensuring there is a strong antibiotics pipeline to fight secondary infections and over the counter medications are safe and secure.

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation -  Issues related to supporting programs and institutions supporting during the current pandemic. 

S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. 

H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. 

Issues related to creating a listing mechanism for dietary supplements. 

Issues related to the implementation on the SUPPORT Act (P.L. 115-271)","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-11T21:07:04.037000-04:00
2506038,570e38b7-8569-4600-ba8d-8a705f978f1f,Q3,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2020,third_quarter,PHA,"H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. 

The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. 

H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders.

Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. 

H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans. 

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.

H.R. 6201 - Families First Coronavirus Response Act  -Implementation -  Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 748 - The CARES Act - Implementation-  Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation -  Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. 

H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.

S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. 

Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-12T10:23:34.667000-04:00
2506277,cbdb09e1-fffd-4cbc-9d48-03f40e77a5c8,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY),2020,third_quarter,PHA,Issues related to the cost of care and protecting patient access to blood cancer treatment.  Issues related to specialty drug tiers.  Issues related to Presidential Executive Orders regarding drug pricing.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-12T15:26:14.697000-04:00
2506363,56de192c-4e38-4b2c-856b-cf1d8f283e5e,Q3,HOLLAND & KNIGHT LLP,18466,"TEVA PHARMACEUTICALS USA, INC.",2020,third_quarter,PHA,Global supply chain issues; National Defense Authorization Act.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-10-12T17:49:16.380000-04:00
2506621,570d47f5-2763-4858-a52b-b68353f7fb5f,Q3,"PARAGON BIOSCIENCES, LLC",401105338,"PARAGON BIOSCIENCES, LLC",2020,third_quarter,PHA,Issues related to public and private investment in biosciences and R&D,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2020-10-13T11:25:03.227000-04:00
2506632,6bc37521-3cf5-487d-b59b-7a9841ba24bf,Q3,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2020,third_quarter,PHA,"The Prescription Drug Pricing Reduction Act S. 2543-IPC supports.
Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale.
Support regulations that would eliminate pharmacy DIR.
IPC supports Pharmacists as providers under Medicare Part B
IPC supports Pharmacists as Immunizers
IPC supports 340B Program and contract pharmacies
First Families Coronavirus Response Act 2020. IPC supports
The Coronavirus Aid, Relief and Economic Security Act 2020. IPC supports","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,30000,0,0,2020-10-13T11:34:14.607000-04:00
2506710,bd9a7475-c311-4091-af34-a2c35b2c2b2e,Q3,THE KUTLER GROUP,401103966,PRIME THERAPEUTICS,2020,third_quarter,PHA,"drug pricing issues
monitor Covid 19 legislation","HOUSE OF REPRESENTATIVES,SENATE",24000,,0,0,2020-10-13T12:18:15.017000-04:00
2506831,778a6351-3b8f-4939-a0c1-d643b64c02de,Q3,"OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC",30212,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2020,third_quarter,PHA,"Drug pricing, Direct and Indirect remuneration fees, Medicare, COVID-19","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2020-10-13T13:59:02.813000-04:00
2506980,1bac0306-16ea-4f78-a1dc-6664459610fa,Q3,"BOLD STRATEGIES, LLC",401104653,"MORRIS & DICKSON CO., LLC",2020,third_quarter,PHA,Prescription drug issues generally.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-13T15:25:13.163000-04:00
2507137,c91fc14d-5ada-445c-8190-c8e1b856018c,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2020,third_quarter,PHA,"Issues related to drug pricing in the pharmaceutical supply chain.  Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to the implementation of PL 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions.  Issues related to H.R. 6800, the Heroes Act.  Issues related to proposals that would address drug shortages and national stockpile issues.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-13T17:38:01.273000-04:00
2507365,69e60df4-b158-43ae-9eb5-a1f813456ceb,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2020,third_quarter,PHA,"Drug coverage & reimbursement

no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay

H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 1895 - Lower Health Care Costs Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-14T10:32:12.683000-04:00
2507386,ff703277-7849-4c35-aec0-7bfb9261defc,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2020,third_quarter,PHA,"H.R. 1781 - Payment Commission Data Act of 2019
H.R. 938 - the BLOCKING Act of 2019
H.R. 1520 - the Purple Book Continuity Act of 2019
H.R. 1503 - the Orange Book Transparency Act of 2019
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R. 965 - the CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions For Patients Act of 2019 
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019


no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2020-10-14T10:38:16.740000-04:00
2507503,d33eeb22-a071-42e3-86b6-e3026c1e2d04,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2020,third_quarter,PHA,"General issues related to over the counter pharmaceuticals and pharmaceutical supply chain.  Implementation of the Over the Counter Monograph provisions included in PL 116-136, Coronavirus Aid, Relief and Economic Security Act.  Issues related to supplements.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-14T11:35:51.567000-04:00
2507589,36a6a35f-ffe8-41f6-ae89-05414a5a94a6,Q3,SUMMIT PUBLIC AFFAIRS,401105467,VANDA PHARMACEUTICALS INC.,2020,third_quarter,PHA,"Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues.
Administration of the 21st Century Cares Act (Pub. L. No. 114-255).
Administration of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (Pub. L. No. 116-136).
COVID-19 Clinical Trials.
H.R. 7608, Agriculture, Rural Development, FDA, and Related Agencies Appropriations for FY2021, provisions regarding FDA testing for new drug applications.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-14T12:44:23.780000-04:00
2507614,ed30b2ff-da64-4745-bf92-e39d11dc7b21,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,"GLENMARK PHARMACEUTICALS, INC., USA",2020,third_quarter,PHA,"General information about the company and the industry.  Issues related to affordability and pricing of pharmaceuticals.  Issues related to the implementation of H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including drug supply chain dynamics.  H.R. 6800, the HEROES Act. 
S. Amdt 2652, the Targeted COVID Relief Package.  Issues related to the federal response to the COVID-19 pandemic.  Supply chain and essential medicine manufacturing.","Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-14T13:06:35.537000-04:00
2508429,29e2e46e-0b2f-4ad8-b689-ad92576c9ded,Q3,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2020,third_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2020-10-14T23:46:39.977000-04:00
2508432,0eb8e85f-0add-496c-b4b0-6c00882fecef,Q3,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2020,third_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2020-10-14T23:47:40.643000-04:00
2508435,44bc882c-cc1b-4505-bb41-1b204662ca38,Q3,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2020,third_quarter,PHA,"H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE",22500,,0,0,2020-10-14T23:48:41.220000-04:00
2508437,d6aa502f-70d7-400c-bc99-0f8d6b7fc514,Q3,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2020,third_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2020-10-14T23:50:41.707000-04:00
2508442,3f03fb29-4bd7-4122-a632-bf1cccbcf418,Q3,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2020,third_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2020-10-14T23:51:42.397000-04:00
2508445,7856830a-045d-48c3-8cb4-604fb974bc12,Q3,ROCK & ASSOCIATES,33545,PRECISION PHARMACY,2020,third_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2020-10-14T23:52:42.957000-04:00
2508576,7f7b549d-acc4-4c7a-b997-9051b75ee71a,Q3,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2020,third_quarter,PHA,"H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019;
H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019;
H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019;
H.R. 5198, the Patients' Right to Know Their Medication Act of 2019;
H.R. 5304, the PBM Transparency in Prescription Drug Costs Act;
Draft Long Term Care pharmacy definition legislation","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office",,330000,0,0,2020-10-15T10:03:20.690000-04:00
2508583,b726e06b-f5ff-4a18-9f81-db96b03a0cab,Q3,WAXMAN STRATEGIES,401103693,340B HEALTH,2020,third_quarter,PHA,Issues affecting the 340B drug pricing program; Appropriations for 340B program.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-15T10:05:23.650000-04:00
2508670,340381f4-4ce3-4e44-b70f-86a26d249765,Q3,WINNING STRATEGIES WASHINGTON,50796,KALEO,2020,third_quarter,PHA,"Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-15T10:36:45.417000-04:00
2508678,91b5f46a-4bb6-4bb2-a9b7-488a94a3ff32,Q3,NATIONAL RURAL HEALTH ASSOCATION,53048,NATIONAL RURAL HEALTH ASSOCATION,2020,third_quarter,PHA,The 340B Program and drug pricing,"Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE",,29156,0,0,2020-10-15T10:36:47.620000-04:00
2508787,cc0b42e8-1521-48f4-a2cc-ed4a9fe6cac8,Q3,AARP,1694,AARP,2020,third_quarter,PHA,"S. 2543, the Prescription Drug Pricing Reduction Act. 
 
H.R. 7288, the Taxpayer Research and Coronavirus Knowledge (TRACK) Act.

No bill number. Discussed COVID-19 vaccine development, approval, and distribution.

No bill number. Discussed mail-order prescription drugs. 

H.R. 19/S. 3129, Lower Cost More Cures Act. 

H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act.","Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Federal Communications Commission (FCC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Indian Health Service,Internal Revenue Service (IRS),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of the Comptroller of the Currency (OCC),Pension Benefit Guaranty Corporation (PBGC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office",,1880000,0,0,2020-10-15T11:03:12.777000-04:00
2509235,4e0e29fe-053b-44cc-9017-23b311c1ba76,Q3,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2020,third_quarter,PHA,"Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number).

Mandatory recall authority of the FDA

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.

H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020

S.930 - Allowing Greater Access to Safe and Effective Contraception Act

S.1847/H.R. 3296 - Affordability is Access Act

S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020

H.R.6058 - SHOP SAFE Act of 2020

S.3431 - INFORM Consumers Act

Legislation to increase domestic production of pharmaceuticals and the domestic supply chain. 

H.R. 6395 - National Defense Authorization Act for Fiscal Year 2021
S.4049 - National Defense Authorization Act for Fiscal Year 2021

HR 8179 - Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020","Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,Vice President of the U.S.",,140000,0,0,2020-10-15T12:33:17.327000-04:00
2509823,fbd10f32-6de9-4a03-a2c4-eeb24ca276b5,Q3,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2020,third_quarter,PHA,"Opioids; CREATES Act; Drug Pricing

HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration.

HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin.

HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain.

HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office",,160000,0,0,2020-10-15T16:22:00.710000-04:00
2509827,94261a95-6dbb-49e4-a1f6-876551daf93c,Q3,LUNGREN LOPINA LLC,401103314,AMPAC FINE CHEMICALS,2020,third_quarter,PHA,Fair treatment for US based pharmaceutical ingredients,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-15T16:23:02.210000-04:00
2510008,d37db5a7-5167-4be5-9a98-180968b55c3e,Q3,POLSINELLI PC,314911,"TEVA PHARMACEUTICALS USA, INC.",2020,third_quarter,PHA,"S. 2543, Prescription Drug Pricing Reduction Act
S. 1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
Coronavirus stimulus legislation 
Review of Administration drug pricing and telehealth policies
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-10-15T17:11:45.260000-04:00
2510311,bfd69f49-8ade-42be-ba28-98f437c9f12d,Q3,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2020,third_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-16T08:20:02.117000-04:00
2510370,006b6e06-916d-47fc-979d-43d0e5a4845d,Q3,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2020,third_quarter,PHA,"Educate Members on pharmacy contracting with pharmacy benefit managers
Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing
S 1895 Lower Healthcare Costs Act
HR 2296 Fair Accountability and Innovative Research Drug Pricing Act
HR 2376 Prescription Pricing for the People Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-16T09:17:19.930000-04:00
2510592,8b803559-0a90-40d5-ab5b-d02294f41cf8,Q3,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2020,third_quarter,PHA,"S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019; H.R. 4812-Ensuring Compliance Against Drug Diversion Act of 2019;  H.R. 4806-Tthe Debarment Enforcement of Bad Actor Registrants Act of 2019; H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020; HR 7574-Strengthening America's Strategic National Stockpile Act of 2020.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-16T10:35:08.080000-04:00
2511119,57b6ec7b-e2ce-4c10-bd9e-350ca836d0ee,Q3,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2020,third_quarter,PHA,Monitor Data and Science Policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-16T13:18:27.680000-04:00
2511390,9b637d25-9dc7-4598-8d61-5d0d0df4f084,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,ACER THERAPEUTICS,2020,third_quarter,PHA,"COVID 19 therapeutics and Medical Countermeasures, Rare Disease and Re-purposed drugs","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-16T14:30:37.973000-04:00
2511472,6c70c870-e0f7-4dc0-9f22-5e1a7d9ec617,Q3,CAPITOL COUNSEL LLC,313715,VERTEX PHARMACEUTICALS INCORPORATED,2020,third_quarter,PHA,Monitoring and advocacy on matters related to the pharmaceutical industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-16T14:45:10.557000-04:00
2511572,d949897b-8b04-4afd-9acb-c0ace67423d0,Q3,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2020,third_quarter,PHA,"Any bill(s), provision(s), or action(s) impacting the 340B Drug Discount Program and hospitals and health systems ability to provide access to these drugs for patients. 
Any bill(s) or provision(s) addressing high drug prices.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,57250,0,0,2020-10-16T15:08:42.583000-04:00
2511582,477d1e44-3018-4e5d-9837-4a3485169a6c,Q3,SAFEWAY INC.,300173,SAFEWAY,2020,third_quarter,PHA,"CMS Medicaid Part D Final Rule, provisions related to DIR Fees

H.R. 1034, S. 640 - Phair Pricing Act, all provisions

H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions

Issues related to pharmacist provider status

S 2543 - Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing.


HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees","HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2020-10-16T15:09:43.717000-04:00
2511625,ee302a00-4131-4770-adae-686f5bdc951b,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2020,third_quarter,PHA,"Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)
Issues related to ARCOS data and suspicious order record requirements and reporting 
Importation of Prescription Drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844, Public Law 108-173) 
Implementation of Public Law 113-54 (DSCSA) 
Block, Report, And Suspend Suspicious Shipments Act of 2019 (H.R. 3878) 
Debarment Act (H.R. 4806)
Ensuring Compliance Against Drug Diversion (H.R. 4812)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-10-16T15:17:57.550000-04:00
2511742,eb31f149-6d0b-4026-b330-fbd2bbc70496,Q3,E3 STRATEGIC CONSULTING GROUP,401104104,HEINZ STRATEGIES LLC (ON BEHALF OF PILMA),2020,third_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-16T15:57:30.757000-04:00
2511743,fa6572cb-8d91-4bd0-9e6a-60c97e661f87,Q3,E3 STRATEGIC CONSULTING GROUP,401104104,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2020,third_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-16T15:58:31.343000-04:00
2511799,f950f01f-5dd6-4049-99e9-11a3390c7702,Q3,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2020,third_quarter,PHA,"Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)
Issues related to ARCOS data and suspicious order record requirements and reporting 
Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) 
Implementation of Public Law 113-54 (DSCSA) 
Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) 
Debarment Act (HR 4806)
Ensuring Compliance Against Drug Diversion (HR 4812)
Suspicious Order Identification Act of 2019 (S. 2686, HR 4814)","Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,336505,0,0,2020-10-16T16:07:42.640000-04:00
2512113,2531cb51-99a2-4e7b-b2a7-cb5121c02fff,Q3,340B HEALTH,316434,340B HEALTH,2020,third_quarter,PHA,"The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 4538, Closing Loopholes for Orphan Drug Act; S. 3631, Relief for Rural Providers During Emergencies Act; S. 4160, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; S. 4199, A bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes; H.R. 7838, To provide for certain temporary waivers with respect to the 340B drug discount program due to the COVID-19 public health emergency, and for other purposes.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,267118,0,0,2020-10-16T17:00:02.517000-04:00
2512114,8a884644-0b74-4467-a659-31304f8ce498,Q3,PENN AVENUE PARTNERS,400918672,"ALKERMES, INC.",2020,third_quarter,PHA,"Regulatory and legislative issues impacting Alkermes.
S.3312: Crisis Stabilization and Community Reentry Act of 2020.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-16T17:01:03.057000-04:00
2512347,fb5d62ab-3388-4dae-a9ab-bdc61a23a12e,Q3,LINCOLN PARK GROUP L.L.C.,401104374,CANADIAN INTERNATIONAL PHARMACY ASSOCIATION,2020,third_quarter,PHA,Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-16T18:16:58.283000-04:00
2512480,d4cc1c72-fcb7-404f-8c2c-c41e2aff132b,Q3,"BROWN & FORTUNATO, P.C.",401104878,"PROMPTCARE COMPANIES, INC.",2020,third_quarter,PHA,"Issues related to Medicare home infusion therapy benefit and other health care issues.  Issues related to the Medicare DMEPOS competitive bidding program.  Issues related to H.R. 4945 - Safeguarding Medicare Access to Respiratory Therapy Act of 2019; H.R. 1865 - Further Consolidated Appropriations Act, 2020; H.R. 748 - CARES Act; H.R. 6201 - Family First Coronavirus Response Act.  Issues related to H.R. 6218 and S. 3457 - The Preserving Medicare Access to Home Infusion Act.",Centers For Medicare and Medicaid Services (CMS),20000,,0,0,2020-10-16T21:11:36.353000-04:00
2512524,20267e43-b643-40c9-a768-7020ddb36a57,Q3,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2020,third_quarter,PHA,"Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care, prescription drugs and generic drugs. Issues related to continuation of prescription drug access and testing during COVID crisis. Issues related to Medicare Part D rebates.","HOUSE OF REPRESENTATIVES,SENATE",55000,,0,0,2020-10-17T08:32:04.173000-04:00
2512539,8b3ae8bc-d99f-41ad-998f-ccd03eb912ce,Q3,BROYDRICK & ASSOCIATES,7268,EXELA PHARMA SCIENCES,2020,third_quarter,PHA,Drug shortages and FDA approval. USTR acceptance.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-17T09:39:10.910000-04:00
2512556,be61c632-c851-43dd-9d26-792da7ad74f7,Q3,BROYDRICK & ASSOCIATES,7268,TONIX PHARMACEUTICALS,2020,third_quarter,PHA,Funding new drug for PTSD.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-17T09:57:18.553000-04:00
2512819,cb6701a2-6491-4ed0-a28b-f1bd306d95e8,Q3,PUBLIC CITIZEN,32362,PUBLIC CITIZEN,2020,third_quarter,PHA,"H.R. 7296 (MMAPPP Act); H.R. 7288 (TRACK Act); Patents for Humanity Program Improvement Act; transparency for federally support covid R&D; covid-19 medicine pricing and access, Drug pricing, Covid 19 Medicine pricing, manufacture and access,","HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE",,100000,0,0,2020-10-17T14:48:09.177000-04:00
2513637,d16566d5-43ed-481e-9adb-0c8e3b3b22c8,Q3,FORBES-TATE,400976792,MERCK,2020,third_quarter,PHA,"Issues related to prescription drug pricing, vaccines, animal health, and maternal health.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-18T15:19:31.293000-04:00
2513717,55b9ff1c-3cb8-40cd-9301-1dcca29d5fe0,Q3,FORBES-TATE,400976792,PHRMA,2020,third_quarter,PHA,Issues pertaining to prescription drug pricing.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-10-18T16:15:50.400000-04:00
2514034,ff2614dd-9035-453a-ae9b-f4336cb913f0,Q3,FOLEY & LARDNER LLP,15042,BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY),2020,third_quarter,PHA,Market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-18T22:04:25.330000-04:00
2514075,83a3e55a-8654-4480-a8c2-a6a8e4325049,Q3,FOLEY & LARDNER LLP,15042,"ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY",2020,third_quarter,PHA,FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market.,"HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2020-10-18T22:18:38.913000-04:00
2514102,b4ef9aac-56f0-44a4-96b7-4598b6f27508,Q3,FOLEY & LARDNER LLP,15042,FOUNDATION CONSUMER HEALTHCARE LLC,2020,third_quarter,PHA,legislation and regulations affecting marketing and commercialization of prescription and non-prescription drugs,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-18T22:25:45.383000-04:00
2514291,9b31bdd7-73ac-4315-80b7-3573b7bc2c85,Q3,"FREEDOMWORKS, INC.",9330,"FREEDOMWORKS, INC.",2020,third_quarter,PHA,EO 13948 - Lowering Drug Prices by Putting America First;,"Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,220000,0,0,2020-10-19T03:07:26.807000-04:00
2514377,be765bf7-8de1-4814-8396-7fe1c5c1f7e0,Q3,VAN SCOYOC ASSOCIATES,39837,ZEBRA TECHNOLOGIES CORP.,2020,third_quarter,PHA,"Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation 

Temperature monitoring technology for COVID-19 vaccines","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-19T06:03:48.630000-04:00
2514487,c6e17a8c-f116-473c-9f60-86ac3a18eabb,Q3,BALLARD PARTNERS,401104288,AVITA PHARMACY,2020,third_quarter,PHA,HRSA 340B Program,"Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),White House Office",30000,,0,0,2020-10-19T07:36:11.397000-04:00
2514567,c222b726-3ba8-41cf-b17b-86b15191a9e6,Q3,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2020,third_quarter,PHA,GFI 256 FDA Compounding Guidance;,"Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Treasury, Dept of",240000,,0,0,2020-10-19T08:35:25.593000-04:00
2514641,664e68df-ea2c-4955-a6bd-ee5b7c69f206,Q3,UC HEALTH,401103195,UC HEALTH,2020,third_quarter,PHA,340B,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-19T09:05:43.447000-04:00
2514697,b48e5d29-3a73-42a8-9f5a-a3fa7371a3e6,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,AIM IMMUNOTECH INC.,2020,third_quarter,PHA,Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics.,"Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE",30000,,0,0,2020-10-19T09:16:54.987000-04:00
2514862,a4d90054-7587-48f6-8319-84342ab33749,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,NOVO NORDISK INC.,2020,third_quarter,PHA,"H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; H.R. 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act)","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE",60000,,0,0,2020-10-19T09:38:42.623000-04:00
2514937,d2febacb-7ee1-46b5-84fb-7532a0235c8d,Q3,"FLYNN & ASSOCIATES, INC.",15020,PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION,2020,third_quarter,PHA,"Drug Price controls
Drug importation from Canada","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-19T09:51:00.510000-04:00
2514982,59aaf6a0-b8f7-4e5d-99c0-fc85acfe3904,Q3,COVINGTON & BURLING LLP,11195,1776 PHARMACEUTICALS LLC,2020,third_quarter,PHA,Re-shoring production of essential medicine,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-19T09:55:08.747000-04:00
2515270,78dd0264-dd86-4446-a162-cd6b6b13b9e4,Q3,"GENENTECH, INC",15920,GENENTECH INC,2020,third_quarter,PHA,"S.2543: Prescription Drug Pricing Reduction Act of 2019.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
S.551, REFUND Act of 2019
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program

- Drug pricing issues
- Prescription Drug User Fee Act reauthorization
- Issues related to prescription drug value","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",,2710000,0,0,2020-10-19T10:22:12.217000-04:00
2515293,e821f3fc-0340-41cb-97c1-691d93d0d5fe,Q3,"POLITICAL CAPITAL, LLC",401104260,MEDISCA INC,2020,third_quarter,PHA,"Guidance documents, compounding pharmacy, appropriations language.","Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-19T10:25:17.797000-04:00
2515319,53976853-27af-479e-b3b2-3266bc374594,Q3,"POLITICAL CAPITAL, LLC",401104260,STOKES PHARMACY,2020,third_quarter,PHA,Compounding,"Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-19T10:28:24.197000-04:00
2515536,43fb3219-f1ed-4f85-9345-f8c1c920ed4f,Q3,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2020,third_quarter,PHA,Monitoring biotech legislation; prescription drug prices,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-10-19T10:53:20.183000-04:00
2515558,333d9a28-7a1a-4926-b434-f3a03d49c8b1,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,"PHARMACEUTICAL ASSOCIATES, INC.",2020,third_quarter,PHA,Strategy development and implementation of company's federal government relations initiatives.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-19T10:55:28.077000-04:00
2515815,c0da3886-c676-4140-a554-b9b3a164f2aa,Q3,HOGAN LOVELLS US LLP,18422,"ALVOGEN, PHARMA US, INC.",2020,third_quarter,PHA,Issues related to COVID-19,"HOUSE OF REPRESENTATIVES,SENATE",220000,,0,0,2020-10-19T11:19:19.653000-04:00
2516094,28c5daa5-bb0d-407a-bf5e-ebe4974d316d,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL),2020,third_quarter,PHA,"Illicit prescription drug sales online; rouge internet drug sellers; dangers of counterfeit medicines; risks of drug importation on patient safety; domain name system accountability regarding COVID-19 frauds; WHOIS; Communications Decency Act, Section 230 reform","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",70000,,0,0,2020-10-19T11:43:19.367000-04:00
2516138,d54cb81a-9c50-4855-9f17-558d3bca6eff,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,NATIONAL ASSOCIATION OF BOARDS OF PHARMACY,2020,third_quarter,PHA,"Medication safety, pharmacy regulation, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R. 2482, S. 2074 - Mainstreaming Addiction Treatment Act; opposing prescription drug importation","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-19T11:46:32.347000-04:00
2516271,b4890e41-a8be-47a3-86d9-6e5140b99739,Q3,MR. VINCENT A. PANVINI,401008845,PHRMA,2020,third_quarter,PHA,"Position on Price Controls; patent Protections, Importation of Biopharmaceuticals.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-19T11:57:02.237000-04:00
2516598,852b9d39-df62-43d9-a93e-c63513f9afd7,Q3,HANCE SCARBOROUGH,17443,PHRMA,2020,third_quarter,PHA,Patent reform regarding pharmaceutical research & products.,SENATE,30000,,0,0,2020-10-19T12:28:21.850000-04:00
2516854,4d87537d-b5de-402e-8bc1-d575d3dde800,Q3,HANCE SCARBOROUGH,17443,BOEHRINGER INGELHEIM USA CORPORATION,2020,third_quarter,PHA,"Provide ongoing animal health policy monitoring, assessment, and research support. Telemedicine/telehealth legislation.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-19T12:48:25.917000-04:00